>
-NOVAGOLD Reports Third Quarter 2022 Financial Results-Sports Bra Market Size to Surpass $95324.6 Million by 2028, Exhibit a CAGR of 12.1% – Industry Trends & Forecast Report by Facts & Factors-Diversified Royalty Corp. Announces October 2022 Cash Dividend-Lightbridge CEO Seth Grae to Appear on GB News Tomorrow at 7:00 am ET-Mettler-Toledo International Inc. to Host Third Quarter 2022 Earnings Conference Call-Compass Diversified Declares Third Quarter 2022 Distributions on Common and Series A, B and C Preferred Shares-U.S. Experiencing “Stimulus Hangover, Not a Recession”-With 4.31% CAGR, Piston Engine Aircrafts Market Size to Hit USD 1.15 Billion by 2028 – Comprehensive Research Report by Facts & Factors (FnF)-Gold Reserve Announces Stock Option Grants-Memphis-based VC firm Ridgeline Launches Oversubscribed $52m Fund I-Velodyne Lidar adquiere la empresa de software de IA Bluecity-Multi Touch Screens Market Size to Hit $20952.66 Mn by 2028 | Multi Touch Screens Industry Striking CAGR of 13.17%-Statistical Report on Metaverse Market Size to Hit $730.5 Bn by 2028 | Metaverse Industry Striking CAGR of 23.2% – Report by Facts & Factors (FnF)-Miami-Dade Homeless Trust Chairman Ron Book Remarks on HOMES Plan Conference-Best’s Market Segment Report: U.S. Title Insurers Post Solid Results for 2021 Amid Volatile Landscape-Oncodesign Precision Medicine (OPM) Announces its IPO Through Direct Listing on Euronext Access + Paris-Survey: Investors Showcase Shift in Fixed Income Strategies Amid Search for Higher Returns-[Latest] Global Concrete Floor Coatings Market Size/Share Worth 8.3 Billion by 2030 at a 6.5% CAGR: Custom Market Insights (Report, Trends, Forecast, Trends, Segmentation)-Shoppers’ Expectations of Tech at Retail are High Yet Often Unmet, New ChaseDesign|JGA Survey Shows-Automotive LiDAR Sensors Market Expected to Generate $11.7 Billion By 2031: Allied Market Research

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RADNOR, Pa.–()–Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to 13 new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 132,375 shares of its common stock (the “Common Stock”) and the grant of restricted stock units to purchase an aggregate of 20,500 shares as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

These stock option grants have an exercise price of $5.26 per share, which is equal to the closing price of the Common Stock on July 14, 2022 (date of grant for such stock options). All of the stock options will vest and become exercisable as to 25% of the underlying shares on the one-year anniversary of the applicable employee’s start date of employment, and will vest and become exercisable as to the remaining 75% of the underlying shares of Common Stock in 36 equal monthly installments thereafter on each monthly anniversary, subject to the applicable employee’s continued employment with Marinus on such vesting dates. These restricted stock units vest in full on the first anniversary of the applicable employee’s start date of employment. The stock options and restricted stock units were granted as an inducement material to each of the employees entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the applicable award agreement covering such grant.

About Marinus Pharmaceuticals

Marinus is a commercial stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit www.marinuspharma.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.

Leave a Comment